“Historically, we’ve always been on old school paper based systems. Having to analyze and draw together all of the data from different sources is really challenging, and it's not a nice process."
“We benchmarked a lot of different solutions. One of the solutions we started using was a competitor of Benchling, but it was super heavy to put in place, and we weren’t very happy about it; we started using Benchling two years ago."
“At Gilead, we’re committed to creating a healthier world for everyone by discovering, developing and delivering medicines for life-threatening diseases. This work requires managing highly complex, multi-dimensional data and necessitates technology partners that can support the scale and complexity of the data created by high-throughput biology. We selected Benchling as a partner because it’s built for biology. By capturing structured data in Benchling, our scientists are empowered to ask challenging questions and uncover new insights.”
“Our experiments are based on two pillars, One is based on assay development — mostly in vitro assay development and in vivo assay development — and the other is formulation improvement.”
“The first time you run a campaign, FRAGLER will identify duplicate DNA sequences and help you save up to 50% of the cost of synthetic DNA synthesis by enabling fragment recycling."